Optimizing antibody development through recombinant antibody services

Recombinant antibodies, as opposed to conventional hybridoma antibodies, have recently gained popularity due to their distinct benefits in high-throughput production and widespread antibody expression. The resultant recombinant antibodies, however, are identical in terms of specificity, activity, and structure to their traditional hybridoma counterparts.

Optimizing antibody development through recombinant antibody services

Image Credit: ACROBiosystems

This implies that recombinant antibodies can be highly beneficial to the wide range of applications that use antibodies, such as immunodiagnostics and other biologics-based analytical studies.

ACROBiosystems offers a versatile, one-stop solution for recombinant antibody production demands, ranging from the various requirements of research and development scientists to the substantial volumes required by pharmaceutical manufacturers.

Optimizing antibody development through recombinant antibody services

Image Credit: ACROBiosystems

To address the rising demand for custom antibody reagents used in drug discovery and preclinical research, ACROBiosystems, a leading provider in the biopharmaceutical industry, has spent the last ten years developing and optimizing its recombinant antibody technology platform.

This comprises a platform for the expression of mammalian cells that have been independently refined and is based on HEK293 and CHO cells, in addition to having experience in the large-scale manufacture of antibody reagents.

ACROBiosystems offers a one-stop solution that covers the whole antibody production workflow, from collecting antibody sequence information (or VH/VL information) to providing high-purity, low-endotoxin recombinant antibodies and offering services for switching antibody class.

ACROBiosystems offers services for producing recombinant antibodies in quantities ranging from grams to kilograms in accordance with the standard of endotoxin levels of less than 1EU/mg. They also optimize the culture and production process according to the customer’s large-scale manufacturing demands.

Recombinant Antibody Protein Services from ACROBiosystems strive to deliver prompt, high-quality recombinant antibodies that satisfy each customer’s requirements, whether it be timely delivery (as little as two weeks for the delivery of custom recombinant antibodies) or specific specifications (including yield, concentration, etc.); in keeping with its commitment to its customers to provide “Better Design, Better Quality, Better Support, and Better Customer Experience.”

ACROBiosystems aims to meet and surpass the demands of its customers.

About ACROBiosystems

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jan 27, 2024 at 3:44 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2024, January 27). Optimizing antibody development through recombinant antibody services. News-Medical. Retrieved on May 19, 2024 from https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx.

  • MLA

    ACROBiosystems. "Optimizing antibody development through recombinant antibody services". News-Medical. 19 May 2024. <https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx>.

  • Chicago

    ACROBiosystems. "Optimizing antibody development through recombinant antibody services". News-Medical. https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx. (accessed May 19, 2024).

  • Harvard

    ACROBiosystems. 2024. Optimizing antibody development through recombinant antibody services. News-Medical, viewed 19 May 2024, https://www.news-medical.net/whitepaper/20230301/Optimizing-antibody-development-through-recombinant-antibody-services.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.